TORONTO, Canada September 20, 2005 Generex Biotechnology Corporation (NasdaqSC: GNBT), a leader in the area of buccal drug delivery, today announced that Dr. Jaime Guevara-Aguirre, of the Institute of Endocrinology IEMYR in Quito, Ecuador and one of the principal investigators in the Company's on-going clinical trials of Oral-lyn, its proprietary oral insulin spray product, will make the following presentations of Oral-lyn clinical trial results at the 7th Joint Meeting Paediatric Endocrinology of the European Society of Paediatric Endocrinology and the Lawson Wilkins Pediatric Endocrine Society to be held in Lyon, France from September 21 - 24, 2005:
A 12-Day Comparison of Preprandial Humulin vs. Oral-lyn in 10 Type 1 Diabetic Subjects Receiving Baseline Glargine Insulin Therapy, scheduled for poster presentation on September 22, 2005. The study is coauthored by Marco Guevara and Jeannette Saavedra.
A Series of Open-Label Studies Comparing Various Formulations of Orally Administered Insulin (Oral-lyn) in Patients with Type-1 Diabetes Mellitus (DM), scheduled miniposter (oral) presentation with slideshow on September 22, 2005. The study is coauthored by Marco Guevara and Jeannette Saavedra.
The European Society of Paediatric Endocrinology is an international organization with several hundred members from over 45 countries whose aim is to promote the highest levels of knowledge, research, education and clinical practice of paediatric endocrinology and metabolism throughout the world.
The mission of the Lawson Wilkins Pediatric Endocrine Society is to promote the acquisition and dissemination of knowledge of endocrine and metabolic disorders from conception through adolescence.
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Companys proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Companys proprietary RapidMist device. The Companys flagship product, oral insulin (Oral-lyn), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world.
For more information, visit the Generex Web site at www.generex.com.
Safe Harbor Statement:
This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
# # #
